Anti-VEGF Injection in Moradabad — Advanced Eye Care with Dr. Deeksha Singh at Jigyasa Hospital

Who Is Dr. Deeksha Singh?

Dr. Deeksha Singh is an ophthalmology specialist at Jigyasa Hospital, Moradabad, who offers Anti-VEGF injection therapy for wet age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinal vein occlusion, and other retinal vascular disorders. She evaluates patients with advanced retinal disease and manages long-term treatment schedules to preserve and, where possible, improve vision.

Her approach combines detailed retinal assessment, advanced OCT imaging, and individualized injection plans, along with clear counseling on the importance of timely treatment and consistent follow-up to protect vision over the long term.

Introduction

Vision loss caused by retinal disease can be frightening, but for many patients it is also highly treatable. Over the last two decades, Anti-VEGF (anti-vascular endothelial growth factor) therapy has transformed the outlook for people living with wet age-related macular degeneration, diabetic retinopathy, diabetic macular edema, and retinal vein occlusion. What was once a condition that often led to irreversible blindness can now, in many cases, be stabilized or even improved with a simple outpatient injection.

For residents of Moradabad and the surrounding districts of Western Uttar Pradesh, access to this kind of specialised retinal care used to mean travelling to Delhi, Lucknow, or other metro cities. That is changing. At Jigyasa Hospital in Moradabad, the Ophthalmology department, led by Dr. Deeksha Singh, now offers Anti-VEGF injection therapy locally, backed by modern diagnostic equipment and a patient-first approach to eye care.

This article explains what Anti-VEGF therapy is, which conditions it treats, what the procedure involves, and why timely treatment matters — along with why patients in Moradabad are increasingly choosing Jigyasa Hospital for this treatment.

What Is Anti-VEGF Therapy?

VEGF, or Vascular Endothelial Growth Factor, is a protein naturally produced by the body. In healthy tissue, it plays a useful role in forming new blood vessels. But in certain eye diseases, the retina produces VEGF in excess. This triggers two damaging processes: abnormal blood vessel growth (neovascularization), where fragile new vessels grow where they shouldn't, particularly under or within the retina, and increased vascular leakage, where elevated VEGF makes existing retinal blood vessels leaky, causing fluid to accumulate in the macula — the part of the retina responsible for sharp, central vision. This fluid buildup is called macular edema.

Anti-VEGF drugs work by binding to and neutralizing VEGF molecules in the eye. This reduces leakage, discourages abnormal vessel growth, and allows swelling in the retina to subside. The medication is delivered directly into the vitreous cavity (the gel-filled space inside the eye) through a quick injection — a procedure called an intravitreal injection.

Commonly used Anti-VEGF agents include bevacizumab, ranibizumab, aflibercept, and newer formulations, with the choice depending on the specific diagnosis, disease severity, and the treating ophthalmologist's clinical judgment.

Conditions Treated with Anti-VEGF Injections

1. Wet (Neovascular) Age-Related Macular Degeneration (AMD)

Wet AMD is a leading cause of severe vision loss in people over 50. It occurs when abnormal blood vessels grow beneath the macula and leak blood or fluid, causing rapid, often severe central vision distortion. Left untreated, wet AMD can progress to significant vision loss within weeks to months. Anti-VEGF therapy is currently the standard first-line treatment and has been shown to stabilize vision in most patients, with many experiencing meaningful improvement when treatment begins early.

2. Diabetic Retinopathy and Proliferative Diabetic Retinopathy (PDR)

Uncontrolled or long-standing diabetes damages the tiny blood vessels of the retina. As the disease advances, the retina may respond by growing fragile new vessels (proliferative diabetic retinopathy), which can bleed into the eye or pull on the retina, risking retinal detachment. Anti-VEGF injections help regress these abnormal vessels and reduce the risk of vision-threatening complications, often used alongside laser photocoagulation.

3. Diabetic Macular Edema (DME)

Even without proliferative changes, diabetes can cause fluid to accumulate in the macula, blurring central vision. DME is one of the most common causes of vision impairment in working-age diabetic adults. Anti-VEGF injections are highly effective at reducing this swelling and are now considered a primary treatment option for centre-involving DME.

4. Retinal Vein Occlusion (RVO)

When a retinal vein becomes blocked — whether a branch vein (BRVO) or the central retinal vein (CRVO) — blood and fluid back up into the retina, often triggering significant macular edema and sudden, painless vision loss. Anti-VEGF therapy helps reduce this swelling and can support meaningful visual recovery, particularly when started soon after diagnosis.

5. Myopic Choroidal Neovascularization (CNV)

Patients with high (pathological) myopia can develop abnormal vessel growth under the retina, similar to wet AMD but occurring at a younger age. Anti-VEGF injections are the treatment of choice here as well.

6. Other Indications

Anti-VEGF therapy may also be used for neovascular glaucoma, certain cases of central serous chorioretinopathy with CNV, and other retinal vascular disorders, based on individual assessment.

Why Early Diagnosis Matters

A recurring theme across all these conditions is that outcomes are strongly time-dependent. Retinal tissue that has been damaged by prolonged swelling or bleeding does not always recover fully, even after the underlying cause is treated. This is why ophthalmologists emphasize regular eye check-ups for anyone over 50, and annual retinal screening for all diabetics, regardless of whether vision problems are noticed.

Immediate consultation is important for sudden blurring, distortion of straight lines (metamorphopsia), a dark or blank patch in central vision, or sudden vision loss in one eye. Consistent follow-up once treatment begins is also essential, since these are typically chronic conditions requiring an ongoing treatment schedule rather than a single injection.

The Anti-VEGF Injection Procedure: What to Expect

Many patients feel anxious at the idea of an "eye injection," but the procedure is brief, well-tolerated, and performed as a routine outpatient visit. A typical session at Jigyasa Hospital follows this sequence: pre-injection evaluation with visual acuity testing and imaging (usually OCT, and sometimes fundus fluorescein angiography) to confirm the diagnosis and assess disease activity; sterile preparation with thorough cleaning and anesthetic drops; the injection itself using a very fine needle into the vitreous cavity; brief post-injection checks; and recovery instructions.

Most patients resume normal daily activities the same day, though mild grittiness, redness, or the sensation of a floating spot in vision for a day or two is common and expected.

Treatment Frequency

Anti-VEGF therapy is rarely a one-time treatment. Depending on the condition and how the eye responds, patients may need an initial "loading phase" of monthly injections (commonly three consecutive doses) to bring the disease under control, followed by ongoing maintenance injections spaced out based on disease activity — anywhere from monthly to once every few months — determined through regular OCT monitoring. Long-term follow-up is important, since chronic conditions like wet AMD and diabetic eye disease can remain active for years.

Your ophthalmologist will tailor the exact schedule to your specific diagnosis and how your eye responds over time.

Safety and Possible Side Effects

Anti-VEGF injections have an extensive safety record built on many years of clinical use worldwide. That said, as with any medical procedure, patients should be aware of possible effects. Common and mild effects include temporary eye redness, mild discomfort, a gritty sensation, or seeing small floating spots for a short period after injection. Uncommon effects can include increased eye pressure or mild inflammation inside the eye.

Rare but serious complications include infection inside the eye (endophthalmitis), retinal detachment, or bleeding. These are infrequent when the procedure is performed under sterile conditions by a trained ophthalmologist, but patients should seek immediate medical attention if they experience severe pain, sudden vision loss, or worsening redness after an injection.

Discussing your full medical history — including any allergies, prior eye surgeries, or systemic conditions — with your ophthalmologist before treatment helps minimize risk.

Why Patients in Moradabad Choose Jigyasa Hospital

Jigyasa Hospital has positioned itself as a multi-speciality healthcare provider in Moradabad, and its Ophthalmology department under Dr. Deeksha Singh brings several advantages for patients needing Anti-VEGF therapy.

Frequently Asked Questions